Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846041 | 0.87 | TRPV1 (0.67) | KDRTRPV1KDM4ERAB9ANPC1 | |
| SCHEMBL846202 | 0.87 | TRPV1 (0.67) | KDRTRPV1KDM4ERAB9ANPC1 | |
| SCHEMBL846040 | 0.87 | TRPV1 (0.67) | KDRTRPV1KDM4ERAB9ANPC1 | |
| SCHEMBL846722 | 0.78 | TRPV1 (0.73) | KDRTRPV1KDM4ERAB9ALMNA | |
| SCHEMBL28421769 | 0.78 | NOTUM (0.52) | KDRTRPV1KDM4ERAB9ANPC1 | |
| SCHEMBL846592 | 0.78 | TRPV1 (0.73) | KDRTRPV1KDM4ERAB9ALMNA | |
| SCHEMBL845848 | 0.71 | TRPV1 (0.78) | KDRTRPV1KDM4ERAB9ANPC1 | |
| SCHEMBL6705159 | 0.71 | CFTR (0.40) | KDRKDM4ERAB9ANPC1TSHR | |
| SCHEMBL6426978 | 0.71 | TRPV1 (0.47) | KDRTRPV1 | |
| SCHEMBL6386609 | 0.69 | KDR (0.44) | KDRTRPV1KDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | KDR 704/4885TRPV1 1/4885KDM4E 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.